Literature DB >> 14692712

DCE-MRI in clinical trials: data acquisition techniques and analysis methods.

R Strecker1, K Scheffler, M Büchert, K Mross, J Drevs, J Hennig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14692712     DOI： 10.5414/cpp41603

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  6 in total

1.  Spatially regularized T(1) estimation from variable flip angles MRI.

Authors:  Hesheng Wang; Yue Cao
Journal:  Med Phys       Date:  2012-07       Impact factor: 4.071

2.  A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents.

Authors:  Julio Cárdenas-Rodríguez; Christine M Howison; Terry O Matsunaga; Mark D Pagel
Journal:  Magn Reson Imaging       Date:  2013-04-11       Impact factor: 2.546

3.  Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Authors:  K K Y Cham; J H E Baker; K S Takhar; J A Flexman; M Q Wong; D A Owen; A Yung; P Kozlowski; S A Reinsberg; E M Chu; C-W A Chang; A K Buczkowski; S W Chung; C H Scudamore; A I Minchinton; D T T Yapp; S S W Ng
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

4.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

Review 5.  Molecular imaging as a tool for translating breast cancer science.

Authors:  David A Mankoff
Journal:  Breast Cancer Res       Date:  2008-12-09       Impact factor: 6.466

6.  Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.

Authors:  Klaus Mross; Martin Büchert; Annette Frost; Michael Medinger; Peter Stopfer; Matus Studeny; Rolf Kaiser
Journal:  BMC Cancer       Date:  2014-07-11       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.